Results 141 to 150 of about 14,435 (170)

Methylprednisolone/nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +1 more source

Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.

Clinical Infectious Diseases, 2023
Louis Saravolatz
exaly  

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study

Vaccines, 2022
Riccardo Scotto, Giuseppe Castaldo, Antonio Riccardo Buonomo   +2 more
exaly  

Nirmatrelvir/Ritonavir/Tacrolimus

Reactions Weekly
  +6 more sources

Real-world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID-19: A retrospective cohort study

Journal of Medical Virology, 2023
Pinhua Pan, Furong Zeng, Li-Ping Jin
exaly  

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS

Pharmaceuticals, 2022

exaly  

Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.

Open Forum Infectious Diseases, 2022
Michael Usher, Nicolas Hoertel
exaly  

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source

Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis

Journal of Medical Virology, 2023
Zhaoyan Chen, Fangyuan Tian
exaly  

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

International Journal of Antimicrobial Agents, 2023
Iker Falces-Romero, Francesco Marchesi, Oliver A. Cornely   +2 more
exaly